The purpose of this announcement is to enter into agreements with pharmaceutical companies

Company within the meaning of § 130a sec. 8 sentence 1 SGB V. The invitation to participate may only be sent to:

pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of

of § 4 Abs. 18 Arzneimittelgesetz. It is not an open procedure according to § 15 VgV

in conjunction with § 119 Abs. 3 GWB, but a publication of the invitation to conclude/join of/

discount agreements with non-negotiable conditions fixed for all participants, including

the amount of the discount. Contractual partners may have an unlimited number of pharmaceutical companies or

Employee associations of pharmaceutical companies within the meaning of § 4 Abs. 18 Arzneimittelgesetz.

The purpose of this announcement is to conclude agreements on the active ingredient "abatacept (ATC code: L04AA24)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-05@kbs.de sent to KBS.

The earliest start date of the contract is 01.07.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.06.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.05.2025. In any case, the contracts end on 30.06.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "Risperidone dosage form: PLI (ATC code: N05AX08)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-05@kbs.de sent to KBS.

The earliest start date of the contract is 01.07.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.06.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.05.2025. In any case, the contracts end on 30.06.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "Isotonic saline solution - medicinal products pharmacy-only dosage forms: AMP, ILO, INF (ATC code: V07AB)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Social Security Code, Fifth Book (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-05@kbs.de sent to KBS.

The earliest start date of the contract is 01.07.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.06.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.05.2025. In any case, the contracts end on 30.06.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "Iron(III) dosage form: ILO (ATC code: B03AC)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the Fifth Book of the German Social Code (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-05@kbs.de sent to KBS.

The earliest start date of the contract is 01.07.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.06.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.05.2025. In any case, the contracts end on 30.06.2025.

The purpose of this announcement is to conclude agreements on the active ingredient "Milnacipran dosage form: ICP (ATC code: N06AX17)" with pharmaceutical companies within the meaning of Section 130a (8) sentence 1 of the German Social Code, Fifth Book (SGB V) (discount agreements). Pursuant to Section 130a (8) sentence 1 SGB V, the invitation to participate is addressed only to pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG). It is not an open procedure, but a publication of the invitation to conclude/join discount contracts with non-negotiable conditions set for all participants, including the amount of the discount. The corresponding information in section IV.1.1) is due only to the scheme of this form. An unlimited number of pharmaceutical companies or employee groups of pharmaceutical companies within the meaning of Section 4 (18) of the German Medicines Act (AMG) can become contractual partners. The information in section II.2.5) is due to the system of this publication form. The conclusion or accession of the contract takes place by the required completed self-declarations or evidence as well as the contract or contracts either:

a) Signed by hand (written form according to § 126 BGB) by mail or

b) Provided with a qualified electronic signature (§ 126a BGB) by e-mail to openhouse.rabattvertrag2023-05@kbs.de sent to KBS.

The earliest start date of the contract is 01.07.2023, provided that the contract and the required declarations or evidence have been received by KBS by 05.06.2023 at the latest. The commencement of the contract is therefore the 1st of the month following the month in which the contract is received by KBS and the required declarations or proofs, provided that it is received by the 5th of each month; otherwise the 1st of the month after next. The contracts shall terminate automatically, without the need for termination, as soon as the contracting party(s) or combination of active substances has been determined by means of a formal award procedure. The deadline for the receipt of accessions is 05.05.2025. In any case, the contracts end on 30.06.2025.